Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery

Updated 05/03/2024

Status Recruiting

Clinical Trial Summary

The purpose of this conversion therapy study is to evaluate the safety and efficacy of neoadjuvant of Tislelizumab combined with platinum doublet for stage III unresectable locally advanced NSCLC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

NSCLC, Stage III

Clinical Trial Details

NCT number	NCT05611879
Study type	Interventional
Source	Beijing Tsinghua Chang Gung Hospital
Contact	Fan Yang, Dr.
Phone	+86-10-56112345
Email	Yfa01087@btch.edu.cn
Status	Recruiting
Phase	Phase 2
Start date	March 12, 2023
Completion date	April 30, 2024

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT05386888` - A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC	Phase 2
	Recruiting	`NCT05128630` - Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.	Phase 2
	Active, not recruiting	`NCT05027165` - Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
	Recruiting	`NCT05311709` - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities	Phase 2
	Recruiting	`NCT05718297` - Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Phase 2
	Recruiting	`NCT04351256` - Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy	Phase 2
	Active, not recruiting	`NCT04392505` - Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study	Phase 2
	Recruiting	`NCT05757843` - Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab	Phase 2
	Recruiting	`NCT04952168` - Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC	Phase 2
	Recruiting	`NCT04830826` - A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
	Active, not recruiting	`NCT03999710` - Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer	Phase 2
	Recruiting	`NCT03454685` - The Role of Microbiota on the Development of Lung Cancer
	Not yet recruiting	`NCT05177497` - SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC	Phase 2
	Recruiting	`NCT04202809` - Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.	Phase 2
	Recruiting	`NCT04585490` - Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC	Phase 3
	Recruiting	`NCT04654364` - Lung Cancer Registry
	Recruiting	`NCT05344209` - Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer	Phase 2
	Withdrawn	`NCT03130829` - To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC	N/A
	Recruiting	`NCT04680377` - Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients